Literature DB >> 20347931

Cyclins and their related proteins in pituitary tumourigenesis.

Mădălina Muşat1, Damian G Morris, Márta Korbonits, Ashley B Grossman.   

Abstract

Pituitary tumours are benign neoplasms that may cause major endocrine dysfunction. Transgenic disruption of the cell cycle machinery frequently leads to pituitary adenoma formation in animal models. The molecular analysis of human pituitary tumours has found various alterations in the expression of cell cycle regulators: cyclins, cyclin-dependent kinases and their inhibitors. There are also different mechanisms (e.g. hypermethylation, frameshift mutations, increased proteasome degradation) responsible for changed expression in cyclin mRNA and protein. It is probable that the primary initiating events lie beyond the cell cycle and may be related to co-activation of Akt, MAP-kinase and beta-catenin pathways. Nevertheless, molecular CDK inhibitors may play a role in pituitary tumour treatment in the future. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347931     DOI: 10.1016/j.mce.2010.03.017

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  10 in total

1.  Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.

Authors:  Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

2.  Silence of p15 expression by RNAi enhances cisplatin resistance in hepatocellular carcinoma cells.

Authors:  Dianliang Fang; Yuanhong Guo; Zhenshuang Zhu; Weiqing Chen
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

3.  Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.

Authors:  Henriett Butz; Kinga Németh; Dóra Czenke; István Likó; Sándor Czirják; Vladimir Zivkovic; Kornélia Baghy; Márta Korbonits; Ilona Kovalszky; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Pathol Oncol Res       Date:  2016-12-21       Impact factor: 3.201

4.  Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique.

Authors:  Guang Shan; Tian Tang
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

Review 5.  New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases.

Authors:  Hidenori Fukuoka
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

6.  Knockdown of COPS3 Inhibits Lung Cancer Tumor Growth in Nude Mice by Blocking Cell Cycle Progression.

Authors:  Jianan Pang; Xu Yan; He Cao; Lei Qian; Hua He; Huimin Tian; Fujun Han; Guanjun Wang; Xiao Chen; Yuguang Zhao; Ji-Fan Hu; Jiuwei Cui
Journal:  J Cancer       Date:  2017-04-09       Impact factor: 4.207

7.  Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system.

Authors:  Wei Han; Wei Li; Xiaoying Zhang; Zhonghua Du; Xiaoliang Liu; Xin Zhao; Xue Wen; Guanjun Wang; Ji-Fan Hu; Jiuwei Cui
Journal:  Oncotarget       Date:  2017-02-28

8.  Clinical significance and biological roles of cyclins in gastric cancer.

Authors:  Hai-Ping Zhang; Shu-Yu Li; Jian-Ping Wang; Jun Lin
Journal:  Onco Targets Ther       Date:  2018-10-09       Impact factor: 4.147

9.  Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.

Authors:  Yanju Wu; Qianqian Zheng; Yan Li; Guang Wang; Shuting Gao; Xiaodong Zhang; Xu Yan; Xinwen Zhang; Jisheng Xie; Yuanyuan Wang; Xun Sun; Xin Meng; Bo Yin; Biao Wang
Journal:  J Exp Clin Cancer Res       Date:  2019-08-27

Review 10.  Architects of Pituitary Tumour Growth.

Authors:  Maria Eugenia Sabatino; Ezequiel Grondona; Ana Lucía De Paul
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.